非处方药市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

在预测期内,非处方药 (OTC) 药物市场预计将以 8.5% 的复合年增长率增长。

市场快照

molecular diagnostics market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.65 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

在预测期内,全球非处方药市场预计将以 6.65% 的复合年增长率增长。该市场的增长推动因素是产品创新、新兴市场的高渗透率、有利的监管框架以及制药公司对处方药非处方药的倾向。

未来几年,全球非处方药 (OTC) 药物市场可能在拉丁美洲和东南亚新兴市场创下最高增长率。这可以归因于人口的快速增长,加上这些地区中产阶级的增长和人口可支配收入的增加,这将增加可用于获得非处方药的人口的临界数量。除了零售店在新兴市场的可及性新渠道外,超市也为新兴经济体非处方药市场的增长做出了贡献。

报告范围

根据本报告的范围,非处方药被称为非处方药。这些药物可以在没有医生处方的情况下由个人购买,并且在没有医生同意的情况下可以安全食用。

By Product Type
Cough, Cold, and Flu Products
Analgesics
Dermatology Products
Gastrointestinal Products
Vitamins, Mineral, and Supplements (VMS)
Weight-loss/Dietary Products
Ophthalmic Products
Sleeping Aids
Other Product Types
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacy
Other Distribution Channels
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

减肥和膳食产品细分市场预计将以高复合年增长率增长

据信,减肥和饮食产品部门在预测期内的复合年增长率最高,为 8.10%。这主要归因于普通民众对健康意识的提高和垃圾食品消费的增加,这导致与生活方式相关的疾病增加。VMS(维生素、矿物质和补充剂)细分市场被认为拥有最大的市场份额。  

VMS 和减肥 OTC 药物对整个市场的贡献最大。事实上,近 1/4 的市场属于这一细分市场。这一主要份额的原因是该类别下各种产品的庞大客户群。与其他性质强烈的条件不同,VMS 和减肥条件并不是很麻烦。针对这些情况的非处方药产品比治疗或治愈产品更具有预防性。这就是为什么客户数量比其他适应症的客户数量相对多的原因。庞大的客户群会产生高需求,进而产生高收入。由于不健康人群的增加,VMS产品在发达国家非常受欢迎

Over The Counter (OTC) Drugs-1

预计北美将在预测期内主导市场

北美目前主导着非处方药市场,预计将在未来几年继续占据主导地位。由于制药公司从处方药转向非处方药的领先趋势,预计该地区未来的市场份额将增加。美国国立卫生研究院的报告指出,美国 93% 的成年人在寻求专业护理之前更愿意用非处方药治疗他们的小病,美国 85% 的父母更愿意用非处方药治疗孩子的小病。寻求专业护理之前的非处方药。这导致了更大市场的形成。

Over The Counter (OTC) Drugs-2

竞争格局

非处方药市场竞争激烈,由几个主要参与者组成。就市场份额而言,目前很少有主要参与者主导市场。然而,随着技术进步和产品创新,中小型公司正在通过推出价格更低的新产品来增加其市场占有率。强生公司、诺华公司、拜耳公司、葛兰素史克公司和辉瑞公司等公司在非处方药市场占有重要的市场份额。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Product Innovation

      2. 4.2.2 High Penetration in Emerging Markets

      3. 4.2.3 Favorable Regulatory Framework

      4. 4.2.4 Inclination of Pharmaceutical Companies Toward OTC Drugs from RX Drugs

    3. 4.3 Market Restraints

      1. 4.3.1 Probability of Substance Abuse

      2. 4.3.2 Lack of Awareness in Rural Areas

    4. 4.4 Industry Attractiveness – Porter’s Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Cough, Cold, and Flu Products

      2. 5.1.2 Analgesics

      3. 5.1.3 Dermatology Products

      4. 5.1.4 Gastrointestinal Products

      5. 5.1.5 Vitamins, Mineral, and Supplements (VMS)

      6. 5.1.6 Weight-loss/Dietary Products

      7. 5.1.7 Ophthalmic Products

      8. 5.1.8 Sleeping Aids

      9. 5.1.9 Other Product Types

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Online Pharmacy

      4. 5.2.4 Other Distribution Channels

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 United Kingdom

        2. 5.3.2.2 Germany

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Johnson and Johnson

      2. 6.1.2 Bayer AG

      3. 6.1.3 Mylan NV

      4. 6.1.4 Sanofi

      5. 6.1.5 Pfizer Inc

      6. 6.1.6 GlaxoSmithKline PLC

      7. 6.1.7 Perrigo Company PLC

      8. 6.1.8 Reckitt Benckiser Group PLC

      9. 6.1.9 Takeda Pharmaceutical Company Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Over the Counter Drugs Market market is studied from 2018 - 2026.

The Over the Counter Drugs Market is growing at a CAGR of 6.65% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Johnson and Johnson, Bayer AG, Sanofi, Pfizer, Mylan are the major companies operating in Over the Counter Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!